DE60325725D1 - Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs - Google Patents

Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Info

Publication number
DE60325725D1
DE60325725D1 DE60325725T DE60325725T DE60325725D1 DE 60325725 D1 DE60325725 D1 DE 60325725D1 DE 60325725 T DE60325725 T DE 60325725T DE 60325725 T DE60325725 T DE 60325725T DE 60325725 D1 DE60325725 D1 DE 60325725D1
Authority
DE
Germany
Prior art keywords
mab
monoclonal antibody
diagnosis
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325725T
Other languages
English (en)
Inventor
Claude Prigent
Anne Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Francais du Sang Ets
Original Assignee
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Francais du Sang Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANG BRETAGNE ETS FRANC, Centre National de la Recherche Scientifique CNRS, Francais du Sang Ets filed Critical SANG BRETAGNE ETS FRANC
Application granted granted Critical
Publication of DE60325725D1 publication Critical patent/DE60325725D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60325725T 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs Expired - Lifetime DE60325725D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (1)

Publication Number Publication Date
DE60325725D1 true DE60325725D1 (de) 2009-02-26

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325725T Expired - Lifetime DE60325725D1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7514231B2 (de)
EP (1) EP1511771B1 (de)
JP (1) JP4555681B2 (de)
AT (1) ATE420115T1 (de)
AU (1) AU2003255671A1 (de)
CA (1) CA2489214C (de)
DE (1) DE60325725D1 (de)
FR (1) FR2840905B1 (de)
WO (1) WO2003106500A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255715T3 (es) * 1995-12-18 2006-07-01 Sugen, Inc. Diagnostico y tratamiento de transtornos relacionados con la aur-1 y/o la aur-2.

Also Published As

Publication number Publication date
JP2006513135A (ja) 2006-04-20
WO2003106500A1 (fr) 2003-12-24
CA2489214C (fr) 2013-08-06
AU2003255671A8 (en) 2003-12-31
EP1511771A1 (de) 2005-03-09
AU2003255671A1 (en) 2003-12-31
JP4555681B2 (ja) 2010-10-06
FR2840905A1 (fr) 2003-12-19
FR2840905B1 (fr) 2006-07-07
ATE420115T1 (de) 2009-01-15
US20070117163A1 (en) 2007-05-24
EP1511771B1 (de) 2009-01-07
CA2489214A1 (fr) 2003-12-24
US7514231B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
Li et al. Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
ES2569663T3 (es) Procedimiento de diagnóstico
WO2005084109A3 (en) Cancer specific gene mh15
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
JP2009525478A5 (de)
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
RS51859B (en) METHOD FOR ANTICIPATING THE RESPONSE TO TREATMENT OF HER DIMENSION INHIBITORS
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
Ratkaj et al. Microarray analysis of Dupuytren’s disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway
WO2016203053A3 (en) Methods of characterising cancer
RU2013113314A (ru) Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
Mak et al. Parathyroid hormone-related protein (PTHrP) modulates adhesion, migration and invasion in bone tumor cells
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE331958T1 (de) Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
DE60325725D1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3

Legal Events

Date Code Title Description
8364 No opposition during term of opposition